AzTrials
AzTrials

Paroxysmal Atrial FibrillationCRY-OUT-CATNCT04344743

Balloon Cryoablation Without Contrast

A study testing Cryoballoon ablation without contrast in people with Paroxysmal Atrial Fibrillation, run by Medicover Hospital at 2 sites in Poland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Paroxysmal Atrial Fibrillation
What is being tested?
Cryoballoon ablation without contrast
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
2 sitesPoland
Study dates
13 Aug 2020to Jun 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with paroxysmal AF - episodes lasting up to 7 days or cardioverted before this time
  • At least 4 AF attacks in the last 12 months
  • Informed consent for participation in the study
  • Age > 18 and < 70 years
  • Left atrium diameter (PLAX) < 4,5 cm and left atrial area < = 30 cm2
  • Left ventricle ejection fraction > 45%
  • Four separate veins visualised in computed tomography prior to the ablation

Who cannot join

  • Withdrawal of consent for the procedure
  • Documented typical atrial flutter prior to the ablation
  • Thrombus in left atrium
  • GFR < 60 ml/min
  • Pregnancy
  • Common trunk of left or right pulmonary veins documented on computed tomography (preferred) or by means of other imaging methods
  • Other conditions that preclude AF ablation including: infection, uncontrolled hyperthyroidism, significant anaemia and thrombocytopenia, acute cardiac / internist / surgical conditions

Trial locations and contacts

2 sites in 1 country.

Pawel Derejko, MD, PhD contact

+48603338871

pawel.derejko@medicover.pl

Poland2 sites, 2 recruiting
  • Medicover Hospital

    Warsaw

    Pawel Derejko, MD, PhD, +48603338871, pderejko@yahoo.com

    Marta Sobczynska, MD, +48666308590, marta.sobczynska@medicover.pl

    Recruiting
  • National Institute of Cardiology

    Warsaw

    Michal Orczykowski, MD, PhD, +48696775533, mikeorczyk@gmail.com

    Recruiting

Other trials in Poland

About this study

Official title: Cryoballoon Ablation Without Use of Contrast Dye for the Treatment of Paroxysmal Atrial Fibrillation

Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.

Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.

Read more

All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.

Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.

Read the detailed description

Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.

Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.

All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.

Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.

Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance catheter system as well as future generations of Medtronic cryoballoon catheter systems.

Initially the cryoenergy will be delivered without previous venography confirming full vein occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery, further attempts to isolate the vein will be preceded by venography.

Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to estimate the number and percentage of pulmonary veins that will be isolated without the use of contrast.

The statistical analysis will use standard descriptive statistics tools: frequency tables for categorical variables; extreme values, mean value and standard deviation for normal distributed variables; and extreme values and quartiles for non-normal distributed variables.

Parameters assessed during the procedure:

Concerning a single energy cryoapplication

  1. Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials before the cryoapplication, and after the occlusion of the vein by the balloon.
  2. Time to vein isolation
  3. Cryoenergy application time / freezing time
  4. The minimum temperature obtained during cryoapplication
  5. Time to obtain temperature - 30 ° C and - 40 ° C
  6. Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application
  7. Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein
  8. Total time to complete isolation of a vein
  9. The number of cryoenergy applications
  10. Total time of cryoenergy application per vein Concerning the entire procedure:
  11. Total cryoenergy application time per procedure / patient
  12. The total amount of contrast
  13. Radiation dose
  14. Time of radiation
  15. Left atrial dwelling time
  16. Duration of the procedure (from puncture of the vein to sheaths removal)

Termination of cryoenergy delivery:

  1. If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application (inefficient application).
  2. If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient application).
  3. If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe application).
  4. When temperature reaches - 55° C (unsafe application).
  5. If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are noticed (unsafe application).
  6. If the operator considers that the application is ineffective or performed too distally (inefficient or unsafe application).

Effective cryoenergy applications will be terminated 120 seconds after vein isolation.

Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be isolated - 1 application 240 seconds. Applications will be considered effective if the minimum temperature achieved will be less than 35C and the stimulation performed from the vein after application will be ineffective.

Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered after successful isolation of the vein

Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating entrance and exit block

Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be inflated outside PV ostia and maintained as antrally as possible during vein isolation. For phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation will be performed. Additionally, intermittent fluoroscopy during pacing will be used for monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent phrenic nerve injury.

Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge after index procedure) is considered a minor complication. Death, stroke, tamponade, arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent (if not resolved at end of follow up, but >12 months) phrenic nerve palsy, bleeding with a decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of hospitalization are considered major complications.

The duration of the project and follow-up. The study is expected to last two years. Approximately 50 patients will be enrolled, with one year follow-up. All patients will have follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at 6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study coordinator using standardized questionnaire.

Being tested
Cryoballoon ablation without contrast
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cryoballoon ablation without contrastDevice

    Cryoballoon ablation without contrast

Study groups in NCT04344743
Study groupRoleWhat they receive
Cryoballoon ablation without contrastExperimentalCryoballoon ablation without contrast
Receives: Device: Cryoballoon ablation without contrast

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe

    Acute result will be assessed. Vein isolation assessment will be done using a diagnostic circular catheter (Achieve, Medtronic), by demonstrating entrance and exit block

    Measured: Through study completion, an average of 2 years

Secondary outcomes (7)
  1. Percentage of patients in whom isolation of all pulmonary veins will be achieved without the use of contrast

    Measured: Through study completion, an average of 2 years

  2. Percentage of patients with stable sinus rhythm, without atrial fibrillation episodes during follow-up

    Measured: During one year follow-up

  3. The amount of contrast dye used

    Measured: Through study completion, an average of 2 years

  4. X-ray time exposure

    Measured: Through study completion, an average of 2 years

  5. Radiation dose

    Measured: Through study completion, an average of 2 years

  6. Left atrial dwelling time

    Measured: Through study completion, an average of 2 years

  7. Number of complications assessed

    Measured: Through study completion, an average of 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Apr 2020
  2. Study start13 Aug 2020
  3. Primary completionAug 2021 (estimated)
  4. Study completionJun 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04344743
Sponsor's protocol ID
1_2020
Acronym
CRY-OUT-CAT
Status last verified
Sep 2020
First submitted
5 Apr 2020
Last updated
9 Sep 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, tables,figures, and appendices).

Publications

  • Derejko P, Kusnierz J, Bardyszewski A, Orczykowski M, Dzwonkowska D, Polanska-Skrzypczyk M, Szumowski LJ. Cryoballoon ablation without use of contrast for the treatment of paroxysmal atrial fibrillation. Cardiol J. 2024;31(5):665-674. doi: 10.5603/cj.95969. Epub 2024 Jan 30.

    PubMed 38287689

Questions about this trial

What is this clinical trial studying?

A study testing Cryoballoon ablation without contrast in people with Paroxysmal Atrial Fibrillation, run by Medicover Hospital at 2 sites in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Pawel Derejko, MD, PhD (+48603338871, pawel.derejko@medicover.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe (time frame: Through study completion, an average of 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04344743, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in